Company intelligence / Profile preview

Biocogency

Russia

Ownership: Private
Development stage: Other

Overview

Privately held pharmaceutical/biotech group focused on manufacturing and distributing generic drugs, equipment and drugs for nuclear medicine, and developing high‑technology drugs via vivarium laboratories; financials are reported on a consolidated group basis and it is positioned as a profitable biotech portfolio rather than a clinical‑stage therapeutics developer.[3][10]

Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Rafarma Pharmaceuticals (merger/acquisition relationship, including consolidation of Slavich and related companies and planned addition of Kras Pharma and Bebig to consolidated financials)[3][8][10]

Beyond the preview

Go deeper on Biocogency.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biocogency.

Explore the full profile